NCT04159662 Brain Imaging of Cognition Inn Schizophrenia and Depression
| NCT ID | NCT04159662 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Royal Ottawa Mental Health Centre |
| Condition | Schizophrenia / Schizoaffective Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 90 participants |
| Start Date | 2019-12-12 |
| Primary Completion | 2026-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 90 participants in total. It began in 2019-12-12 with a primary completion date of 2026-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Schizophrenia and depression are among the most disabling disorders in all of medicine. Cognitive deficits play a key role in patients' disability, affecting their capacity to contribute actively to society by sustaining employment or academic activity. Moreover, cognitive difficulties tend to persist even after the stabilization of other clinical symptoms. Verbal memory and emotion regulation are two important cognitive domains that are impaired in schizophrenia and depression and are associated with patients' functional outcomes. In this study, brain imaging is used to investigate the brain mechanisms underlying these cognitive deficits in these populations.
Eligibility Criteria
Inclusion Criteria: * age 18-60 years * current Intelligence Quotient (IQ) \> 70 as measured by the Wechsler Abbreviated Scale of Intelligence (WASI) * the ability to read and speak fluent English * a diagnosis of schizophrenia, schizoaffective or major depression disorder * stable medication for more than one month Exclusion Criteria: * significant neurological or other medical disorders that may produce cognitive impairment * a recent history of substance abuse or dependence (within the past 3 months) * any magnetic resonance imaging (MRI) contraindications (e.g. metallic head implant, history of seizure, pacemaker) * decisional incapacity requiring a guardian * taking medications that are rated as Anticholinergic Burden (ACB) Score 3 (severe) or taking benzodiazepines on a daily basis * Finally, participants could not be severely symptomatic at the time of study enrolment to ensure that they could understand and complete all study assessments. This criterion was defined as a score ≤34 on the Montgomery-Åsberg Depression Rating Scale (MADRS; Montgomery \& Åsberg, 1979) for the MDD group and a score ≤95 on the Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) for the SZ group.
Contact & Investigator
Synthia Guimond, PhD
PRINCIPAL INVESTIGATOR
Royal Ottawa Mental Health Centre
Frequently Asked Questions
Who can join the NCT04159662 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Schizophrenia / Schizoaffective Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04159662 currently recruiting?
Yes, NCT04159662 is actively recruiting participants. Contact the research team at Synthia.Guimond@theroyal.ca for enrollment information.
Where is the NCT04159662 trial being conducted?
This trial is being conducted at Ottawa, Canada.
Who is sponsoring the NCT04159662 clinical trial?
NCT04159662 is sponsored by The Royal Ottawa Mental Health Centre. The principal investigator is Synthia Guimond, PhD at Royal Ottawa Mental Health Centre. The trial plans to enroll 90 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.